Engineered immune cells take on lupus in new trial

NCT ID NCT06189157

Recruiting now Disease control Sponsor: Miltenyi Biomedicine GmbH Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial is testing a treatment called MB-CART19.1, which uses a patient's own immune cells that are modified in a lab to target and destroy faulty cells involved in lupus. It is for adults with severe lupus that has not improved with standard treatments. The study will first find the safest dose and then check if the treatment can put lupus into remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MB-CART19.1 (a type of CAR T-cell therapy made from the patient's own immune cells)
What this could lead to: If this works, it could offer a new treatment option for people with severe lupus that hasn't responded to other therapies, potentially leading to long-term remission without ongoing medication.
What could go wrong: This is an early-phase trial with only 29 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SLE - SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Otto-von-Guericke-Universität Magdeburg
RECRUITING

Magdeburg, Germany
Universitatsklinikum Tubingen - Medizinische Universitätsklinik Abt. II
RECRUITING

Tübingen, Germany
Universitätsklinikum Erlangen, Medizinische Klinik 3
NOT_YET_RECRUITING

Erlangen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.